Home/Filings/4/0001193805-25-001155
4//SEC Filing

DEERFIELD MANAGEMENT COMPANY, L.P. 4

Accession 0001193805-25-001155

CIK 0001374690other

Filed

Aug 3, 8:00 PM ET

Accepted

Aug 4, 6:28 PM ET

Size

36.9 KB

Accession

0001193805-25-001155

Insider Transaction Report

Form 4
Period: 2025-07-31
Deerfield Mgmt HIF, L.P.
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
Deerfield Mgmt IV, L.P.
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
DEERFIELD CAPITAL LP
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
DEERFIELD MANAGEMENT CO /NY
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
Deerfield Mgmt III, L.P.
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
Flynn James E
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
DEERFIELD PARTNERS, LP
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,529$10,840,0939,538,918 total(indirect: Through Deerfield Private Design Fund III, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+3,387,539$10,840,1259,538,945 total(indirect: Through Deerfield Private Design Fund IV, L.P.)
  • Purchase

    Common Stock

    2025-07-31$3.20/sh+2,599,932$8,319,7827,321,129 total(indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Holdings
  • Common Stock

    (indirect: Through Deerfield Partners, L.P.)
    4,207,982
Footnotes (2)
  • [F1]This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
  • [F2]In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Issuer

Larimar Therapeutics, Inc.

CIK 0001374690

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001009258

Filing Metadata

Form type
4
Filed
Aug 3, 8:00 PM ET
Accepted
Aug 4, 6:28 PM ET
Size
36.9 KB